CyFlow™ CD11a Purified
| Alternative Name: | LFA-1 |
| Antibody: | Yes |
| Antigen: | CD11a |
| Application: | Flow cytometry, Functional assays, Immunoprecipitation |
| Clonality: | monoclonal |
| Clone: | MEM-83 |
| Field of Interest: | Immunophenotyping |
| Format/Fluorochrome: | Purified |
| Isotype: | IgG1 |
| Regulatory Status: | RUO |
| Source Species: | Mouse |
| Target Species: | Human |
| Product number: | CS703732 |
For Research Use Only
| Concentration Unit | mg/mL |
| Concentration | 1 |
| Quantity | 0.1 mg |
| Volume | 0.1 mL |
| Immunogen | Human peripheral blood lymphocytes |
| Background Information | CD11a (LFA-1 α) together with CD18 constitute leukocyte function-associated antigen 1 (LFA-1), the αLβ2 integrin. CD11a is implicated in activation of LFA-1 complex. LFA-1 is expressed on the plasma membrane of leukocytes in a low-affinity conformation. Cell stimulation by chemokines or other signals leads to induction the high-affinity conformation, which supports tight binding of LFA-1 to its ligands, the intercellular adhesion molecules ICAM-1, -2, -3. LFA-1 is thus involved in interaction of various immune cells and in their tissue-specific settlement, but participates also in control of cell differentiation and proliferation and of T-cell effector functions. Blocking of LFA-1 function by specific antibodies or small molecules has become an important therapeutic approach in treatment of multiple inflammatory diseases. For example, humanized anti-LFA-1 antibody Efalizumab (Raptiva) is being used to interfere with T cell migration to sites of inflammation; binding of cholesterol-lowering drug simvastatin to CD11a allosteric site leads to immunomodulation and increase in lymphocytic cholinergic activity. |
| Storage Buffer | The reagent is provided in phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide. |
| Storage | Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze. |
| Stability | Do not use after expiration date stamped on vial label. |
| Knapp W, Dorken B, Gilks W, Rieber EP, Schmidt RE, Stein H, von dem Borne AEGK (Eds): Leucocyte Typing IV. Oxford University Press, Oxford. 1989; 1‑1820. < NLM ID: 8914679 > | Landis RC, Bennett RI, Hogg N: A novel LFA‑1 activation epitope maps to the I domain. J Cell Biol. 1993 Mar; 120(6):1519‑27. < PMID: 7680657 > | Landis RC, McDowall A, Holness CL, Littler AJ, Simmons DL, Hogg N: Involvement of the "I" domain of LFA‑1 in selective binding to ligands ICAM‑1 and ICAM‑3. J Cell Biol. 1994 Jul; 126(2):529‑37. < PMID: 7518468 > | Sarantos MR, Raychaudhuri S, Lum AF, Staunton DE, Simon SI: Leukocyte function‑associated antigen 1‑mediated adhesion stability is dynamically regulated through affinity and valency during bond formation with intercellular adhesion molecule‑1. J Biol Chem. 2005 Aug 5; 280(31):28290‑8. < PMID: 15955822 > | Giblin PA, Lemieux RM: LFA‑1 as a key regulator of immune function: approaches toward the development of LFA‑1‑based therapeutics. Curr Pharm Des. 2006; 12(22):2771‑95. < PMID: 16918410 > | Kellersch B, Kolanus W: Membrane‑proximal signaling events in beta‑2 integrin activation. Results Probl Cell Differ. 2006; 43:245‑57. < PMID: 17068975 > | Fujii T, Takada-Takatori Y, Kawashima K: Roles played by lymphocyte function‑associated antigen‑1 in the regulation of lymphocytic cholinergic activity. Life Sci. 2007 May 30; 80(24‑25):2320‑4. < PMID: 17289088 >